Search PubMed⌕ Search

Biomedical subjects

A Ouertani

Publications and source records attributed to A Ouertani.

44 records · Page 3Linked to original sources
PubMedDate not supplied

[Behçet disease in children. 3 Tunisian cases and review of the literature].

OBJECTIVE: To describe epidemiological, clinical and evolutive features of ophthalmological involvment of Behçet disease in children in tunisian patients. PATIENTS AND METHODS: In a retrospective study from 1990 to 1996, we collected three observations in children in 130 recorded cases of Behçet disease. Patients have been explored by a complete ophthalmologic staging and are treated and followed in our institution for theirs oculars problems. RESULTS: The three children, all males, aged from 12 to 13 years, represented 2.3% of all the Behçet disease diagnosed during the same period. Oral and/or genital aphtosis are present in all 3 cases and cutaneous or articular involvement is seen in 2 patients. Ocular Behçet disease involvement, bilateral in all the cases, is dominated by uveitis (posterior in 3 patients or anterior in 2) complicated by macular edema in 3 cases and cataract or pseudo-trou in 1 case. CONCLUSION: Behçet disease in children is characterized by the frequency of familial forms and articular involvement. The most characteristic ocular feature is represented by the posterior uveitis with a visual prognosis poor in short term. Specific criteria of Behçet disease is necessary for children for a early and best identification.

Adolescent↗
PubMedDate not supplied

[Therapeutic results of 5-fluorouracil in multiple and unresectable facial carcinoma secondary to xeroderma pigmentosum].

A prospective study was done to test the efficacy of 5-fluorouracil (topical and systemic) in multiple and unresectable histologically proven facial squamous cell carcinomas (SCC) secondary to XP. Twelve patients (7M/5F, mean age 19.8 years) with multiple facial SCC were treated between 1994 and 1997. 5-FU was used as a twice-a-day local application in the documented areas, by continuous infusion associated with cisplatin (2 patients) and short infusion combined with folic acid (3 patients). Evaluation was done by clinical examination every two months for topical therapy and after every cycle for systemic treatment. Median treatment duration was 12 months (2 to 36 months). Treatment was well tolerated excluding episodes of pruritus in the treated areas. We observed mainly superficial tumour regression followed by dryness and crusting. In 5 cases, we performed biopsies after treatment showing in one case an extensive fibrosis with absence of tumour. However in the remaining 4 cases, despite a superficial reduction of tumour and a reconstitution of the epidermis, viable and unmodified squamous cell carcinoma remained in the deeper dermis. In the 5 patients treated by systemic 5-FU, we observed 1 complete response and 3 partial responses. Despite a dissociation between a good cosmetic result and a relatively superficial effect, topical 5-FU represents a useful therapeutic option in multiple unresectable facial SCC in patients with XP. Systemic chemotherapy is recommended in the event of more extended or profound lesions.

Administration, Topical↗